A tuberculosis diagnosis in a person living with HIV is often a race against time, and sputum-based testing is slow at exactly the moment speed matters most. The urine lipoarabinomannan (LAM) test was built to close that gap, but the World Health Organization does not recommend it for everyone with HIV who might have TB. The eligibility rule is narrow, tied specifically to CD4 count and clinical setting, and understanding why reveals something important about how field diagnostics get matched to the patients they actually help.
What the Test Detects, and Why Urine Is the Sample
Lipoarabinomannan is a component of the mycobacterial cell wall. In active tuberculosis disease, LAM is shed into the bloodstream and filtered into urine, where a lateral-flow immunochromatographic assay can detect it directly on a test strip. There is no analyzer required: a urine sample is applied to the device and a result reads out in around 25 minutes, the same operating logic as a home pregnancy test. That makes urine LAM testing genuinely field-deployable in settings where sputum collection is difficult, sputum smear microscopy is unavailable, or a patient is too unwell to produce a sputum sample at all.
Why WHO Ties Eligibility to CD4 Count, Not Symptoms Alone
WHO updated its guidance on urine LAM testing in 2019, and the resulting recommendation is deliberately narrower than a universal screening tool. The reasoning is that the test’s diagnostic usefulness rises and falls with immune status. In people with more advanced HIV disease and lower CD4 counts, TB is more likely to be disseminated, meaning more mycobacterial antigen circulates and ends up detectable in urine. In people with higher CD4 counts and more localized pulmonary disease, that same antigen burden is often too low for the test to catch reliably. Applying the test outside its evidence base would produce a high rate of missed cases, which is a serious risk for a test being used as a rule-in shortcut rather than a confirmatory diagnostic.
The Threshold, by Setting
WHO’s guidance splits eligibility by whether a patient is admitted to a hospital or being seen as an outpatient, because the underlying acuity of the population differs enormously between the two settings.
| Setting | WHO Recommendation | CD4 Trigger |
|---|---|---|
| Inpatient | Strongly recommended for HIV-positive adults, adolescents, and children with TB signs or symptoms, advanced HIV disease, or serious illness | Also recommended irrespective of symptoms if CD4 is below 200 cells/mm³ |
| Outpatient | Suggested for those with TB symptoms or who are seriously ill | Also suggested irrespective of symptoms if CD4 is below 100 cells/mm³ |
| Outpatient, asymptomatic, higher CD4 | Recommended against, and recommended against when TB symptoms have not been assessed or CD4 is unknown | CD4 of 100 cells/mm³ or higher |
The gap between the two thresholds, 200 in the hospital versus 100 in the clinic, reflects a judgment about pre-test probability. An admitted patient with advanced HIV disease is already a high-risk population where a positive result is more likely to be a true positive; an ambulatory patient with a relatively preserved immune system is not, and testing everyone in that group would generate false reassurance from negative results as often as it generated useful positives.
The Sensitivity Trade-Off Field Teams Have to Accept
Urine LAM testing is not a substitute for confirmatory diagnostics, and its own performance data explains why. Reported sensitivity among HIV-positive patients with confirmed TB has ranged from roughly 35 percent in unselected populations to the high fifties and sixties percent range in symptomatic, hospitalized patients, with specificity generally holding in the 91 to 96 percent range across studies. In practical terms, a negative urine LAM result does not rule out TB, but a positive result in the right clinical context is specific enough to justify starting treatment immediately rather than waiting on slower confirmatory testing. That is the operational role WHO designed it for: a rapid rule-in tool for the sickest, most immunocompromised patients, not a general screening test.
Newer-generation assays are narrowing that sensitivity gap. Comparative data shows a next-generation LAM assay reaching roughly 69 percent sensitivity at CD4 counts under 200 cells/mm³, against roughly 52 percent for the earlier-generation product at the same CD4 range, while both maintain specificity above 90 percent. The direction of travel is toward a tool that performs closer to its inpatient use case even as CD4 thresholds for eligibility are revisited.
What Is Actually on the Market
Despite years of urine LAM being part of WHO guidance, only one commercially available product has WHO prequalification: the Determine TB LAM Ag test, originally marketed under the Alere name and now sold under Abbott’s brand following the 2017 acquisition. WHO has indicated it intends to open prequalification assessments to additional lateral-flow urine LAM assays, which would matter for procurement diversity in programs currently dependent on a single qualified supplier. For a field program building a TB/HIV diagnostic algorithm today, that single-product reality is itself a planning constraint worth building into procurement timelines rather than discovering during a stockout.
The Narrower Lesson
The urine LAM story is a useful case study in diagnostic stewardship: a genuinely useful field tool, correctly restricted to the population where its sensitivity and pre-test probability actually align, rather than deployed as a blanket screen because it happens to be fast and easy to run. For programs managing co-infected patients, the CD4-based eligibility rule is not bureaucratic caution. It is the difference between a test that changes clinical decisions and one that quietly erodes confidence in a diagnosis it was never designed to make.